What AMC cardiology questions actually test
Cardiology is one of the largest single areas inside adult medicine, and it also leaks into emergency medicine, geriatrics, obstetrics and population health. Most questions are not about rare diagnoses. They are about safe decisions in common presentations: a man with chest pain in a rural emergency department, a woman with palpitations in general practice, an older patient breathless at night.
Questions are single best answer with five options. The lead-in usually asks for the most likely diagnosis, the most appropriate next step, the most appropriate investigation, or the best long-term management. The most common reason good candidates lose marks is that two options are both correct medicine, but only one fits the setting and the stage of care described in the stem.
Think of each cardiology stem as three questions stacked together. Is this patient stable or unstable? What is the working diagnosis? What is the very next thing an Australian doctor would do in this setting? If the patient is haemodynamically unstable, the answer is almost always resuscitation or an immediate intervention, not a further test.
- Acute presentations: chest pain, acute coronary syndrome, acute heart failure, tachyarrhythmia, syncope, aortic dissection, tamponade
- Chronic care: hypertension, lipids, absolute cardiovascular risk, stable angina, heart failure medicines, anticoagulation in AF
- Structural disease: valve lesions by murmur, infective endocarditis, cardiomyopathy, rheumatic heart disease
- Overlap areas: ECG reading, drug interactions (warfarin, digoxin, amiodarone), fitness to drive after cardiac events
High-yield topic 1: chest pain and acute coronary syndrome
The exam expects you to sort chest pain quickly into life-threatening causes (ACS, aortic dissection, pulmonary embolism, tension pneumothorax, tamponade, oesophageal rupture) and everything else. The first investigation for suspected ACS is a 12-lead ECG within 10 minutes of arrival. The ECG decides the pathway: ST elevation means reperfusion now; no ST elevation means serial high-sensitivity troponin and risk stratification.
For STEMI, primary PCI is preferred when it can be delivered promptly. In much of rural and remote Australia it cannot, so fibrinolysis, sometimes given by paramedics or rural doctors before transfer, is a real and examinable answer. If a stem places you in a small country hospital hours from a cath lab with a clear STEMI and no contraindications, thrombolysis followed by transfer is usually the expected answer, not waiting for PCI.
For NSTEACS, the exam tests risk stratification (ongoing pain, dynamic ST change, haemodynamic instability, rising troponin) and the timing of angiography. Very high-risk features push towards urgent angiography. Know the core medicines: aspirin early, a second antiplatelet agent, anticoagulation, a statin at high intensity, and beta-blocker and ACE inhibitor when indicated. Do not give a beta-blocker to a patient in cardiogenic shock or acute decompensated heart failure.
- STEMI on ECG plus symptoms: activate reperfusion pathway, do not wait for troponin
- Normal first ECG with ongoing pain: repeat the ECG, it can evolve
- Troponin rise without a typical story: think type 2 MI, myocarditis, PE, sepsis, renal impairment
- Tearing pain to the back, pulse or BP difference between arms, widened mediastinum: dissection until proven otherwise; antiplatelets and thrombolysis are dangerous
- Post-MI secondary prevention: cardiac rehabilitation referral, smoking cessation, dual antiplatelet therapy for a defined period, statin, ACE inhibitor, beta-blocker if reduced LVEF
High-yield topic 2: atrial fibrillation, other arrhythmias and heart failure
Atrial fibrillation questions usually test one of three decisions: rate or rhythm control, stroke prevention, or what to do with an unstable patient. An unstable patient with a tachyarrhythmia (hypotension, shock, chest pain, acute heart failure, reduced consciousness) needs synchronised DC cardioversion. A stable patient needs a decision about rate control, and every patient needs a stroke risk assessment.
This is a key Australian difference. The 2018 NHFA/CSANZ Australian AF guideline uses CHA2DS2-VA, which removes female sex as a risk point. UK and US sources often still teach CHA2DS2-VASc. An Australian answer anticoagulates at a score of 2 or more and considers it at 1. Non-vitamin K oral anticoagulants (DOACs) are preferred over warfarin except in patients with mechanical heart valves or moderate to severe mitral stenosis, where warfarin remains the choice.
Heart failure questions focus on diagnosis (BNP or NT-proBNP and echocardiography), the cause, and drug therapy for heart failure with reduced ejection fraction. Current Australian practice builds therapy on four drug groups: an ACE inhibitor, ARB or ARNI; a heart failure beta-blocker; a mineralocorticoid receptor antagonist; and an SGLT2 inhibitor. Loop diuretics treat congestion but do not change mortality. Know which drugs worsen heart failure: non-dihydropyridine calcium channel blockers in HFrEF, NSAIDs, thiazolidinediones.
- AF onset clearly under 48 hours and stable: cardioversion can be considered; uncertain onset: anticoagulate first or exclude thrombus
- Broad complex tachycardia of uncertain type: treat as ventricular tachycardia
- AF with pre-excitation (WPW): avoid AV nodal blockers such as verapamil, digoxin and adenosine
- Symptomatic bradycardia: atropine, then pacing; look for drug causes (beta-blocker, digoxin, verapamil) and hyperkalaemia
- Acute pulmonary oedema: sit upright, oxygen if hypoxic, IV furosemide, GTN if BP allows, non-invasive ventilation if needed
- Syncope with exertion, a family history of sudden death, or an abnormal ECG: cardiac cause until proven otherwise; admit and monitor
High-yield topic 3: valves, endocarditis, pericardium and cardiomyopathy
Valve questions are usually a murmur plus a history. Aortic stenosis in an older adult presents with exertional chest pain, syncope or breathlessness and an ejection systolic murmur radiating to the carotids; symptom onset is the trigger for valve replacement. Mitral regurgitation is pansystolic at the apex radiating to the axilla. Mitral stenosis in a young woman who grew up in a high-risk community points to rheumatic heart disease.
Rheumatic heart disease is a distinctively Australian topic. Aboriginal and Torres Strait Islander people, especially in northern and central Australia, have some of the highest recorded rates in the world. The exam can test diagnosis of acute rheumatic fever using the Australian guideline (which applies lower thresholds in high-risk groups), notification, and secondary prophylaxis with regular intramuscular benzathine benzylpenicillin. Missed injections are a key cause of progression.
For infective endocarditis, think fever plus a new murmur, injecting drug use, prosthetic valves or recent procedures. Take at least three sets of blood cultures from separate sites before antibiotics unless the patient is septic and unstable. Echocardiography confirms vegetations; transoesophageal echo is more sensitive. In pericarditis, look for pleuritic pain eased by sitting forward, a rub and widespread concave ST elevation with PR depression. Tamponade presents with hypotension, raised JVP and muffled heart sounds and needs pericardiocentesis.
Hypertrophic cardiomyopathy is the classic cause of sudden death in a young athlete. The murmur gets louder with Valsalva and on standing. First-degree relatives need screening. Dilated cardiomyopathy questions often hide alcohol, recent viral illness, pregnancy or chemotherapy as the cause.
- Ejection systolic murmur plus syncope in an older adult: echocardiography, then refer for valve intervention if severe
- Fever plus new regurgitant murmur: blood cultures before antibiotics
- Endocarditis prophylaxis is limited to high-risk cardiac conditions undergoing specific procedures; it is not given for every murmur
- Recurrent pericarditis: colchicine reduces recurrence; avoid anticoagulants if effusion is significant
High-yield topic 4: absolute CVD risk, hypertension and lipids
This is where Australian practice differs most from what many IMGs learned. Australia manages cardiovascular prevention by absolute risk, not by single risk factor thresholds. The 2023 Australian guideline uses the Aus CVD Risk calculator, based on the PREVENT equation and calibrated to the Australian population. It estimates 5-year risk of a cardiovascular event.
Know who to assess: people aged 45 to 79 without known cardiovascular disease, people with diabetes from age 35, and Aboriginal and Torres Strait Islander people from age 30. Risk is classed as high at 10% or more over 5 years, intermediate at 5% to under 10%, and low under 5%. Some people are high risk without a calculation, for example those with moderate to severe chronic kidney disease or familial hypercholesterolaemia. Reclassification factors such as a coronary artery calcium score, family history of premature CVD, severe mental illness and ethnicity can move a person near a threshold up or down.
Management follows risk. High risk usually means blood pressure lowering and lipid lowering medicines plus lifestyle change. Low risk usually means lifestyle advice and reassessment. The exam often presents a patient with a moderately raised reading and asks for the next step; the expected answer is often to calculate absolute risk, not to start a drug.
For hypertension, confirm the diagnosis with out-of-clinic readings (ambulatory or home monitoring) before labelling someone. First-line drug classes are ACE inhibitors or ARBs, dihydropyridine calcium channel blockers and thiazide or thiazide-like diuretics. Beta-blockers are not first-line for uncomplicated hypertension. Look for secondary causes in young patients, resistant hypertension, or hypokalaemia (think primary aldosteronism).
- Single high reading in a well patient: repeat and confirm, then assess absolute risk
- Very high BP with end-organ damage (papilloedema, AKI, encephalopathy): hypertensive emergency, controlled IV lowering in hospital
- ACE inhibitor plus ARB together: avoid; hyperkalaemia and AKI risk
- Statin myalgia: check CK if severe, consider a different statin or dose, do not simply abandon lipid lowering in a high-risk patient
- Pregnancy: ACE inhibitors and ARBs are contraindicated; this is a common distractor
Australian practice differences that change the answer
Many candidates know the medicine but answer from a UK, US, Indian or Middle Eastern guideline. The AMC writes questions for Australian practice. When the best answer depends on a local rule, the local rule wins.
Remember also that the setting matters. A question set in a remote community clinic with a retrieval service hours away tests stabilisation and early discussion with the retrieval team. The same patient in a metropolitan tertiary hospital tests access to immediate cardiology and PCI. Read where the patient is.
- Stroke risk in AF uses CHA2DS2-VA in Australia, not CHA2DS2-VASc
- Primary prevention uses the 2023 Aus CVD Risk calculator and absolute 5-year risk, not 10-year Framingham or QRISK scores
- Rural STEMI: prehospital or early fibrinolysis is a standard Australian pathway when timely PCI is not available
- Rheumatic heart disease and acute rheumatic fever in First Nations communities: diagnosis, notification and penicillin prophylaxis
- Fitness to drive after MI, ICD insertion, syncope or arrhythmia is guided by Austroads Assessing Fitness to Drive; the doctor advises the patient of their duty to report
- Medicines are named by Australian generic names and PBS availability; Therapeutic Guidelines (eTG) sets usual drug choices
How to read a cardiology stem and pick the best answer
Read the lead-in first so you know what you are hunting for. Then read the vital signs before the history. A heart rate of 160 with a systolic BP of 80 changes the answer before you even know the rhythm.
Next, decide the stage of care. In the emergency department the next step is usually an ECG, a bedside test or immediate treatment. In general practice the next step is often confirming a diagnosis, assessing risk or referring. On a ward the next step may be reviewing medicines, checking electrolytes or escalating care.
Finally, check each option against safety. The AMC rewards the safe, guideline-based action. If an option involves sending a patient home with unexplained exertional syncope or chest pain, or giving a thrombolytic to someone with possible dissection, it is wrong no matter how attractive the rest of it sounds.
- Red flags to underline: hypotension, new murmur, syncope on exertion, family history of sudden death, chest pain radiating to the back, pulse deficit
- Next-step logic: stabilise, then diagnose with the simplest decisive test, then treat, then prevent
- If two options are correct, choose the one that should happen first
- If a drug option looks right, check the stem for a contraindication: pregnancy, asthma, renal impairment, bradycardia, hypotension
| Presentation in the stem | Most likely diagnosis | Most appropriate next step |
|---|---|---|
| Central chest pain, ST elevation in II, III, aVF | Inferior STEMI | Reperfusion: primary PCI if timely, otherwise fibrinolysis; check right-sided leads |
| Tearing pain to back, BP differs between arms | Aortic dissection | Urgent CT aortography; control heart rate and BP; no antiplatelets |
| Palpitations, irregularly irregular pulse, BP stable | Atrial fibrillation | Rate control and CHA2DS2-VA score to decide anticoagulation |
| Tachycardia with hypotension and confusion | Unstable tachyarrhythmia | Synchronised DC cardioversion |
| Orthopnoea, oedema, raised JVP, bibasal crackles | Heart failure | BNP or NT-proBNP and echocardiography; diuretic for congestion |
| Exertional syncope, ejection systolic murmur, age 78 | Severe aortic stenosis | Echocardiography and cardiology referral for valve intervention |
| Fever, new murmur, injecting drug use | Infective endocarditis | Three sets of blood cultures before antibiotics, then echo |
| Pleuritic pain better sitting forward, widespread ST elevation | Acute pericarditis | NSAID plus colchicine; echo to exclude effusion |
| Hypotension, raised JVP, muffled heart sounds after trauma | Cardiac tamponade | Urgent pericardiocentesis or surgical drainage |
| BP 152/94 at one visit, age 55, no symptoms | Possible hypertension | Confirm with home or ambulatory readings and calculate absolute CVD risk |
Worked examples in AMC style
Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for cardiology.
Example 1
A 62-year-old man presents to a small rural hospital with 40 minutes of crushing central chest pain. His BP is 138/84 mmHg and heart rate 88/min. The ECG shows 3 mm ST elevation in V1 to V4. The nearest PCI-capable hospital is a three-hour transfer away. He has no history of bleeding, stroke or recent surgery. Aspirin has been given.
What is the most appropriate next step?
-
Primary PCI is preferred only when it can be delivered promptly. A three-hour transfer delays reperfusion beyond the accepted window.
-
STEMI is diagnosed on symptoms and ECG. Waiting for troponin delays reperfusion and loses myocardium.
-
Correct. With a clear anterior STEMI, early presentation, no contraindications and no timely PCI, fibrinolysis followed by transfer is the standard Australian rural pathway.
-
Anticoagulation alone does not reperfuse an occluded artery. It is an adjunct, not the treatment.
-
CT coronary angiography has no role in acute STEMI. It delays treatment and adds nothing to the decision.
Show answer and reasoning
Answer: C. Give fibrinolytic therapy now and arrange urgent transfer
- A. Primary PCI is preferred only when it can be delivered promptly. A three-hour transfer delays reperfusion beyond the accepted window.
- B. STEMI is diagnosed on symptoms and ECG. Waiting for troponin delays reperfusion and loses myocardium.
- C. Correct. With a clear anterior STEMI, early presentation, no contraindications and no timely PCI, fibrinolysis followed by transfer is the standard Australian rural pathway.
- D. Anticoagulation alone does not reperfuse an occluded artery. It is an adjunct, not the treatment.
- E. CT coronary angiography has no role in acute STEMI. It delays treatment and adds nothing to the decision.
STEMI with no timely PCI available: thrombolyse if no contraindication, then transfer.
Based on: NHFA/CSANZ Australian clinical guidelines for the management of acute coronary syndromes
Example 2
A 68-year-old woman sees her GP for review after a 24-hour Holter monitor showed paroxysmal atrial fibrillation. She has treated hypertension and no other medical history. She has never had a stroke, and her renal function and blood count are normal. She asks whether she needs a blood thinner. She takes no other medicines.
Which is the most appropriate advice about stroke prevention?
-
Aspirin is not recommended for stroke prevention in AF. Paroxysmal AF carries stroke risk similar to persistent AF.
-
Anticoagulation is recommended at a CHA2DS2-VA score of 2 or more. Waiting for 3 leaves her exposed to preventable stroke.
-
Warfarin works, but DOACs are preferred in non-valvular AF because they cause less intracranial bleeding and need no INR monitoring.
-
Correct. Age 65 to 74 scores 1 and hypertension scores 1, so CHA2DS2-VA is 2. Australian guidance recommends anticoagulation, preferably with a DOAC. Female sex is not counted.
-
Stroke prevention is based on the risk score, not on seeing a thrombus. A negative echo does not remove the risk.
Show answer and reasoning
Answer: D. Recommend a DOAC as her CHA2DS2-VA score is two points
- A. Aspirin is not recommended for stroke prevention in AF. Paroxysmal AF carries stroke risk similar to persistent AF.
- B. Anticoagulation is recommended at a CHA2DS2-VA score of 2 or more. Waiting for 3 leaves her exposed to preventable stroke.
- C. Warfarin works, but DOACs are preferred in non-valvular AF because they cause less intracranial bleeding and need no INR monitoring.
- D. Correct. Age 65 to 74 scores 1 and hypertension scores 1, so CHA2DS2-VA is 2. Australian guidance recommends anticoagulation, preferably with a DOAC. Female sex is not counted.
- E. Stroke prevention is based on the risk score, not on seeing a thrombus. A negative echo does not remove the risk.
Australia uses CHA2DS2-VA: female sex is not scored; anticoagulate at 2 or more, preferably with a DOAC.
Based on: NHFA/CSANZ Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018
Example 3
A 56-year-old man attends a general practice for a health check. He is a non-smoker without diabetes or known heart disease. His BP is 146/90 mmHg on two readings today. His total cholesterol is 5.9 mmol/L and HDL 1.1 mmol/L. His eGFR and urine albumin-to-creatinine ratio are normal. He is worried about his heart.
What is the most appropriate next step in management?
-
Australian prevention is based on absolute risk, not on one cholesterol value. Starting a statin without assessing overall risk is not the guideline approach.
-
The BP needs confirming with out-of-clinic readings, and the decision to treat depends on his overall risk unless BP is very high.
-
He has no symptoms. Stress testing is not a screening tool for asymptomatic people.
-
Correct. He is in the 45 to 79 age group, so the next step is a 5-year absolute risk estimate, which then guides lifestyle and drug decisions.
-
He has modifiable risk factors and needs a risk estimate now. Waiting five years without assessment misses the chance to prevent disease.
Show answer and reasoning
Answer: D. Estimate his absolute risk using the Aus CVD Risk calculator
- A. Australian prevention is based on absolute risk, not on one cholesterol value. Starting a statin without assessing overall risk is not the guideline approach.
- B. The BP needs confirming with out-of-clinic readings, and the decision to treat depends on his overall risk unless BP is very high.
- C. He has no symptoms. Stress testing is not a screening tool for asymptomatic people.
- D. Correct. He is in the 45 to 79 age group, so the next step is a 5-year absolute risk estimate, which then guides lifestyle and drug decisions.
- E. He has modifiable risk factors and needs a risk estimate now. Waiting five years without assessment misses the chance to prevent disease.
Asymptomatic adult with risk factors: calculate 5-year absolute CVD risk before starting drugs.
Based on: 2023 Australian guideline for assessing and managing cardiovascular disease risk
Quick recall
Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.
Where candidates lose marks
- Scoring female sex in AF
Australian guidance uses CHA2DS2-VA. If you add a point for female sex you may anticoagulate someone the guideline would not.
- Treating a number, not a person
A raised cholesterol or BP in an asymptomatic person usually leads to an absolute risk calculation first, not an immediate prescription.
- Waiting for troponin in STEMI
ST elevation with typical symptoms is enough to start reperfusion. Troponin is for the non-ST elevation pathway.
- Missing dissection
Chest pain to the back with pulse or BP asymmetry must be excluded before giving antiplatelets, anticoagulants or thrombolysis.
- Beta-blocker in acute failure
Beta-blockers help chronic HFrEF but can precipitate shock in acute decompensated heart failure or cardiogenic shock.
How to study cardiology
Day 1: Chest pain triage and ACS. Learn the STEMI and NSTEACS pathways, including the rural fibrinolysis pathway. Do 20 bank questions on ACS.
Day 2: Arrhythmias and AF. Memorise CHA2DS2-VA, the unstable tachycardia rule and AF with WPW. Pair this with the ECG interpretation page.
Day 3: Heart failure and cardiomyopathy. Learn the four HFrEF drug groups, acute pulmonary oedema management and drugs that worsen failure.
Day 4: Valves, endocarditis, pericardium and rheumatic heart disease. Practise murmur-to-diagnosis questions.
Day 5: Prevention. Work through the Aus CVD Risk calculator on three made-up patients, then hypertension and lipid questions.
Day 6: Mixed timed block of 40 cardiology questions. Review every wrong answer and write the one-line rule you missed.
Sources and further reading
Check the current edition of each guideline before your exam. This page is study material, not clinical advice.
- 2023 Australian guideline for assessing and managing cardiovascular disease risk (Aus CVD Risk calculator)
- NHFA/CSANZ Australian clinical guidelines for the management of atrial fibrillation 2018
- NHFA/CSANZ Australian guidelines for the prevention, detection and management of heart failure
- Therapeutic Guidelines: Cardiovascular
- RHDAustralia: Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease
- Austroads: Assessing Fitness to Drive
- Australian Medical Council: MCQ examination